These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19838209)

  • 1. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.
    Sachdev D; Zhang X; Matise I; Gaillard-Kelly M; Yee D
    Oncogene; 2010 Jan; 29(2):251-62. PubMed ID: 19838209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.
    Zeng X; Sachdev D; Zhang H; Gaillard-Kelly M; Yee D
    Clin Cancer Res; 2009 Apr; 15(8):2840-9. PubMed ID: 19351773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.
    Sachdev D; Hartell JS; Lee AV; Zhang X; Yee D
    J Biol Chem; 2004 Feb; 279(6):5017-24. PubMed ID: 14615489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
    Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
    Zeng X; Zhang H; Oh A; Zhang Y; Yee D
    Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
    Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
    PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezrin expression and cell survival regulation in colorectal cancer.
    Leiphrakpam PD; Rajput A; Mathiesen M; Agarwal E; Lazenby AJ; Are C; Brattain MG; Chowdhury S
    Cell Signal; 2014 May; 26(5):868-79. PubMed ID: 24462708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
    Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
    Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
    Zumsteg A; Caviezel C; Pisarsky L; Strittmatter K; García-Echeverría C; Hofmann F; Christofori G
    Mol Cancer Res; 2012 Jun; 10(6):800-9. PubMed ID: 22562956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
    Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
    Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of breast cancer growth and metastasis by a biomimetic peptide.
    Lee E; Lee SJ; Koskimaki JE; Han Z; Pandey NB; Popel AS
    Sci Rep; 2014 Nov; 4():7139. PubMed ID: 25409905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.
    Geoerger B; Brasme JF; Daudigeos-Dubus E; Opolon P; Venot C; Debussche L; Vrignaud P; Vassal G
    Eur J Cancer; 2010 Dec; 46(18):3251-62. PubMed ID: 20591650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.
    Fagan DH; Uselman RR; Sachdev D; Yee D
    Cancer Res; 2012 Jul; 72(13):3372-80. PubMed ID: 22573715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
    Calzone FJ; Cajulis E; Chung YA; Tsai MM; Mitchell P; Lu J; Chen C; Sun J; Radinsky R; Kendall R; Beltran PJ
    PLoS One; 2013; 8(2):e55135. PubMed ID: 23383308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer.
    Niu Z; Li X; Hu B; Li R; Wang L; Wu L; Wang X
    Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):991-8. PubMed ID: 23099883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD24 cell surface expression in Mvt1 mammary cancer cells serves as a biomarker for sensitivity to anti-IGF1R therapy.
    Rostoker R; Ben-Shmuel S; Rashed R; Shen Orr Z; LeRoith D
    Breast Cancer Res; 2016 May; 18(1):51. PubMed ID: 27179633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells.
    Zhang H; Sachdev D; Wang C; Hubel A; Gaillard-Kelly M; Yee D
    Breast Cancer Res Treat; 2009 Mar; 114(2):277-85. PubMed ID: 18418709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
    Moody G; Beltran PJ; Mitchell P; Cajulis E; Chung YA; Hwang D; Kendall R; Radinsky R; Cohen P; Calzone FJ
    J Endocrinol; 2014 Apr; 221(1):145-55. PubMed ID: 24492468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pygenic Acid A (PA) Sensitizes Metastatic Breast Cancer Cells to Anoikis and Inhibits Metastasis In Vivo.
    Lim GE; Sung JY; Yu S; Kim Y; Shim J; Kim HJ; Cho ML; Lee JS; Kim YN
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.